Literature DB >> 26832191

Free Speech and Pharmaceutical Regulation -- Fishy Business.

Amy Kapczynski1.   

Abstract

Mesh：

Substances：

Year:  2016        PMID： 26832191     DOI： 10.1001/jamainternmed.2015.8155

Source DB:  PubMed          Journal:  JAMA Intern Med        ISSN： 2168-6106            Impact factor:   21.873


× No keyword cloud information.
  4 in total

1.  Direct-to-Consumer Broadcast Advertisements for Pharmaceuticals: Off-Label Promotion and Adherence to FDA Guidelines.

Authors:  Kristina Klara; Jeanie Kim; Joseph S Ross
Journal:  J Gen Intern Med       Date:  2018-02-26       Impact factor: 5.128

2.  Assessing the potential clinical impact of reciprocal drug approval legislation on access to novel therapeutics in the USA: a cohort study.

Authors:  Matthieu Larochelle; Nicholas S Downing; Joseph S Ross; Frank S David
Journal:  BMJ Open       Date:  2017-02-08       Impact factor: 2.692

3.  Patterns and predictors of off-label prescription of psychiatric drugs.

Authors:  Aishwarya Vijay; Jessica E Becker; Joseph S Ross
Journal:  PLoS One       Date:  2018-07-19       Impact factor: 3.240

4.  An Uninformative Truth: The Logic of Amarin's Off-Label Promotion.

Authors:  Spencer Phillips Hey; Aaron S Kesselheim
Journal:  PLoS Med       Date:  2016-03-15       Impact factor: 11.069
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.